In vitro cardiac fibroblast cultures are used to examine Cardiogen's effects on fibroblast proliferation, migration, and extracellular matrix-related gene expression, readouts relevant to cardiac tissue remodelling research following injury. Ex vivo cardiac tissue explant models and rodent myocardial injury paradigms (such as ischemia-reperfusion models) are used as complementary systems to study fibroblast-related endpoints in the context of an intact tissue environment rather than isolated cell culture alone.

Rodent models of myocardial injury (including surgically induced ischemia-reperfusion) and hypertension (using pharmacological or surgical induction methods) are standard preclinical systems for studying Cardiogen's effects on cardiovascular stress-response pathways. Typical endpoints include cardiac functional measures (echocardiography-derived ejection fraction, fractional shortening), histological assessment of fibrosis or tissue damage, and molecular markers of stress-response signalling pathways in cardiac tissue samples.

Combination studies typically pair Cardiogen with other bioregulatory peptides or cardiovascular research compounds in the same cell-based or rodent model system, comparing combined treatment effects against each compound administered individually to determine whether observed effects are additive, synergistic, or independent. This comparative experimental design is standard practice for characterising potential interaction effects between bioregulatory peptides studied for overlapping or complementary tissue-specific activity.